Advertisement

Interaction between Cannabis and Other Drugs

  • H. Coper
  • M. Fernandes
Conference paper
Part of the Bayer-Symposium book series (BAYER-SYMP, volume 4)

Abstract

From the drug scene it is well known that the consumption of cannabis is often combined with the abuse of other drugs. Unpredictable interaction effects, in particular an increase in toxicity might be the consequence of such combinations. Experimental work on this subject is rare and only shows that crude cannabis preparations and some of its constituents enhance the barbiturate sleeping time and some amphetamine-effects in small rodents. In view of these sparse results we felt that interaction studies between cannabis extracts or their constituents and other drugs would be of particular interest.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aramaki, H., Tomiyasu, N., Yoshimura, H., Tsukamoto, H.: Forensic chemical study on marihuana. I. A detection method of the principal constituents by thin-layer and gaschromatographies. Chem. pharm. Bull. 16, 822–826 (1968).Google Scholar
  2. Cohen, G. M., Peterson, D. W., Mannering, G. J.: Interactions of d °-Tetrahydrocannabinol with the hepatic microsomal drug metabolizing system. Life Sci. 10, I, 1207–1215 (1971).Google Scholar
  3. Fernandes, M., Coper, H.: Sympos. on the Chem. and Biol. Activ. of Cannabis: The role of vehicles in cannabis application and interaction between cannabis and central active drugs. Acta pharm. Suec. 8, 692–693 (1971).Google Scholar
  4. Nash, T.: The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. Biochem. J. 55, 416–421 (1953).PubMedGoogle Scholar
  5. Paton, W. D. M., Pertwee, R. G.: Effect of cannabis and certain of its constituents on pento- barbitone sleeping time and phenazone metabolism. Brit. J. Pharm. 44, 250–261 (1972).CrossRefGoogle Scholar
  6. Rating, D., Honecker, H., Broermann, I., Strauss, S.: Hexobarbitone sleeping time and amphetamine motility after subchronic tetrahydrocannabinol treatment. Acta Pharmacologica et Toxicologica 29, Suppl. 4, 1971 X XV Scandinavian Pharmacological Meeting, Copenhagen, 1971.Google Scholar
  7. Remmer, H., Schenkmann, I., Estabrook, R. U., Sasame, H., Gillette, I. R., Narasimukulu, S., Cooper, D. Y., Rosenthal, O.: Drug interaction with hepatic microsomal cytochrome. Molec. Pharm. 3, 113–123 (1967).PubMedGoogle Scholar
  8. Schenkmann, J. B., Remmer, H., Estabrook, R. W.: Spectral studies of drug interaction with hepatic microsomal cytochrome. Molec. Pharm. 3, 113–123 (1967).Google Scholar

Copyright information

© Springer-Verlag 1973

Authors and Affiliations

  • H. Coper
    • 1
  • M. Fernandes
  1. 1.Institut für NeuropsychopharmakologieFreie Universität BerlinBerlin 19W. Germany

Personalised recommendations